This week, the Ministry of Human Resources and Social Security released a messageIt was officially announced that Zhang Ke, director of the National Medical Security Administration, took office.
On February 1, People's ** Network released the "** Appointment and Removal of State Workers (February 1, 2024)", appointing Zhang Ke as the director of the National Medical Security Administration. Zhang Ke became the second director of the National Health Insurance Administration since its establishment, and previously had 34 years of audit experience.
This week, multinational pharmaceutical companies have announced their 2023 annual reports.
On January 30, Pfizer announced its 2023 financial resultsAnnual revenue of 584$9.6 billion, down 42% year-on-year, including fourth-quarter revenue of 14.2US$4.9 billion, down 41% year-on-year. In 2023, it will achieve a net profit of 21US$1.9 billion, down 93% year-on-year. Pfizer set its revenue guidance for 2024 at $58.5-$61.5 billion.
On January 31, Novo Nordisk released its 2023 financial reportRevenue was US$33.7 billion, up 31% year-on-year, and net profit was US$12.1 billion, up 52% year-on-year. Among them, the total sales of 3 semaglutide products were 211$5.7 billion.
More hot information compiled by the Health Knowledge Bureau is as follows:
1.The state encourages the development of cell-based drugs
From February 1, the National Development and Reform Commission took the lead and jointly revised the "Industrial Structure Adjustment Guidance Catalogue (2024 Edition)" jointly revised by the National Development and Reform Commission and relevant departments. Cell culture, cell drugs, and high-end intelligent pharmaceutical equipment are listed in the catalogue of encouraged industries.
The Catalogue consists of three categories: encouragement, restriction and elimination. The encouraged category is mainly technology, equipment and products that have an important role in promoting economic and social development. In the catalogue, the pharmaceutical industry includes 5 encouraged categories, 6 restricted categories, and 8 eliminated categories. In the encouraged category, new technologies, new drugs and intelligent equipment technologies are included in a large number of them, and children's drugs, shortage drugs, cell culture, cell drugs, and high-end intelligent pharmaceutical equipment are included in the encouraged industry catalog.
2.The National Health Commission issued the "2024 National Medical Quality and Safety Improvement Goals".
On February 1, the National Health Commission issued the "2024 National Medical Quality and Safety Improvement Goals", aiming to strengthen medical quality and safety management and continuously improve the level of medical quality and safety.
The 2024 National Medical Quality and Safety Improvement Goal retains the 8 goals of 2023, and recalls the two goals of "improving the reperfusion rate of acute ST-segment elevation myocardial infarction" and "reducing the perioperative mortality rate of hospitalized patients".Two new goals have been added: "Improving the Completion Rate of Records Related to Key Diagnosis and Treatment Behaviors" and "Reducing the Rate of Unplanned Return to the Operating Room for Reoperation".Guide the industry to carry out targeted improvement work.
3.36 pharmaceutical brands were selected as time-honored brands in China
On February 1, the Ministry of Commerce issued a notice announcing the third batch of China's time-honored brand list, including the brands of 382 enterprisesAmong them, there are 36 pharmaceutical company brands in the listIncluding Tianjin Lisheng Pharmaceutical, North China Pharmaceutical, Jilin Aodong Pharmaceutical, Huatuo Sinopharm, Luofushan Sinopharm, Sanjin Pharmaceutical, Golden Throat, Kunyao, Sinopharm, Taiji and many other well-known enterprises.
1.CanSino relinquishes control of a significant subsidiary
On February 2, CanSino announced that it would no longer include its subsidiary CanSino in the scope of consolidated statements. CanSino is a new crown vaccine production base jointly invested by Shanghai Pharmaceutical, CanSino Biologics and Shanghai Biopharmaceutical Industry Equity Investment**. When it was established on February 2, 2021, the registered capital was 100 million yuan, and the shareholding ratio of CanSino was 4500%。
On May 17, 2021, CanSino and Shanghai Pharmaceutical added a total of 110.5 billion yuan. In the two years of 2022 and 2023, the total loss of CanSino will reach 103.9 billion yuan.
2.Olin Biotech withdrew the drug registration application for AC-Hib combination vaccine
On February 1, Olin Biotech announced that it received the "Notice of Termination of Drug Registration Application".Agreed with the company to withdraw the registration application for the AC-Hib combination vaccine.
The AC-Hib combination vaccine is suitable for children aged 2 months to 5 years, and can prevent meningitis, pneumonia, sepsis, cellulitis, arthritis, epiglottitis and other infectious diseases caused by meningococcal group A and C meningococcal and Haemophilus influenzae type B. The vaccine submitted a marketing application and was accepted in February 2023The total investment in the research and development of this vaccine is about 59.13 million yuan.
3.Merck K has become the global "king of medicine".
On February 1, Merck announced its 2023 results, with annual revenue of 601US$1.5 billion, up 1% year-on-year, and 9% year-on-year after deducting the impact of the new crown oral drug lagevrio. Among them,K Medicine's annual revenue was 250$1.1 billionWith a year-on-year increase of 19%, it will be crowned the "King of Medicine" in 2023. Sales of the 9-valent HPV vaccine reached 88$8.6 billion, up 29% year-on-year. These two products account for 56% of Merck's total revenue4%。
Merck Sharp & Dohme's pharmaceutical business revenue was 535$8.3 billion, an increase of 3% year-on-year, including:Revenue in China was 67100 million US dollars, occupying 12 of Merck's global market5% share, up 32% year-on-year.
4.Zhang Yuejian resigned as Vice President of Fosun Pharma
On February 1, Fosun Pharma announced that the board of directors received a written resignation letter from Zhang Yuejian. Due to personal reasons, Zhang Yuejian applied to the company's board of directors to resign as vice president. Effective February 1, 2024, Zhang Yuejian will no longer serve as the company's vice president. This is also the third senior executive of Fosun Pharma to leave since 2024.
On January 17, due to personal reasons, Yuan Ning applied to the board of directors of the company to resign as vice president; On January 2, due to her retirement, Ms. Mei Jingping applied to the board of directors of the company to resign as executive president.
5.Inmagene continues to advance two of its drugs
On February 2, Chi-Med announced that Inmagene has exercised its option to license two drug candidates, IMG-007 and IMG-004, discovered by HUTCHMED, pursuant to the terms of the strategic collaboration announced on January 11, 2021. Chi-Med will receive approximately 75% of common stock shares.
IMG-007 is an OX40 antagonistic monoclonal antibody in a global Phase IIA clinical trial in moderate to severe atopic dermatitis and alopecia areata; IMG-004 is an oral BTK inhibitor designed to target immune diseases. For each drug candidate, Chi-MedEntitlement to receive development milestone payments of up to $92.5 million and up to $1$3.5 billionMilestone payments for potential commercial sales, as well as post-commercialization sharing.
1.Hengrui Pharmaceutical's new analgesic drug was launched
On January 31, according to the official website of the State Food and Drug Administration, Hengrui Pharmaceutical's Class 1 innovative drug Tygilidine Fumarate Injection was launched for moderate to severe pain after abdominal surgery.
According to the results of a multicenter study on the epidemiology and management characteristics of postoperative acute pain in China, the incidence of moderate and severe pain after surgery was 487%。AsChina's first self-developed Class 1 opioid analgesic innovative drugTygeridine fumarate injection will provide a new regimen for patients who are deeply troubled by postoperative pain.
2.CSPC GLP-1 initiated a head-to-head test to challenge dulaglutide
January 31, clinicaltrialsgov** displays,CSPC Pharmaceutical Group initiated a head-to-head phase III clinical trial of GLP-1-FC fusion protein TG103 in patients with contrast-dulaglutide** type 2 diabetes.
TG103 is a long-acting recombinant human GLP-1-Fc fusion protein developed by I-Mab in collaboration with Tasly. In 2018, CSPC and I-Mab entered into a collaboration agreement to establish a partnership agreement for 1RMB500 million obtained the exclusive clinical development and commercialization rights of the drug in China.
In August 2023, TG103 entered Phase III clinical trial. In addition to obesity and type 2 diabetes indications, CSPC is also exploring the potential of TG103 for non-alcoholic steatohepatitis and Alzheimer's disease.
3.Kedi Group's finasteride spray was declared for marketing
On January 31, Kedi Group announced that it would use finasteride spray topicallyThe New Drug Application (NDA) for CU-40102 was accepted by the CDE for the treatment of **androgenetic alopecia.
CU-40102 is licensed from Polichem and is a topical formulation of CU-40102 that allows patients to apply the drug directly and precisely to the surface of the scalp, unlike oral finasterideMaintaining a high concentration at the site of medication reduces systemic exposure to the drug, thereby reducing the number of drugs often caused by oral medications
Author丨Fang Taozhi.
Edit |Jiang Yun Jia Ting.
Operations |Twenty-three.
Illustration by Visual China.
Disclaimer: Original content of the Health Knowledge Bureau, please do not do it without permission**